User Community

Advertisement

Quality Experts
@quality-experts
Trusted Member
Joined: Apr 15, 2025
Last seen: Jul 14, 2026
Topics: 0 / Replies: 92
Reply
RE: ICH Q14: software-assisted method development

Yes, I think that the enhanced approach is an incentive to use software-assisted method development. Pieces of software are already used to automate, ...

11 months ago
Reply
RE: Forced degradation testing

I have no experience with CAR and ELISA assay forced degradation. Available guidance, such as the Brazilian ANVISA, Guideline No. 04/2015 focus on che...

11 months ago
Reply
RE: MODR (Method Operating Design Region) as method

I do not have specific information, but I have heard that Pfizer and GSK filed MODRs. Join Dr. Joachim Ermer from Ermer Quality Consulting to le...

11 months ago
Reply
RE: Is there a need for ongoing method validation?

Re: ICH Q2 revision 2 - Yes, thats perfectly true. The initial validation should be regarded as a starting point, i.e. the formal approval of the anal...

11 months ago
Reply
RE: Batch analytical specifications

When only a small number of batches are available, a purely statistical approach cannot be relied upon. Prior knowledge, including data from early dev...

11 months ago
Reply
RE: Batch analytical specifications

Definitely, I would challenge the analytical development team as well as the process team to gather all prior information available from development s...

11 months ago
Reply
RE: DP testing in Europe vs US market

If the drug product (DP) testing scheme is intended for the European market and only Ph. Eur. chapters have been verified, and you wish to apply it to...

11 months ago
Reply
RE: What should you do when you lack sufficient sample analyte to cover the entire specifications range?

The guideline does not go into details. Of course, you must take into account the samples and ranges that are available or accessible. Whether or not ...

11 months ago
Reply
RE: Patient-centric specifications and structure function relationship

"This would be of great help for sure, better knowing and modelling the relationship between structure and function and above all the predictive impac...

1 year ago
Reply
RE: Patient-centric specifications and structure function relationship

"Yes, understanding the structure–function relationship of heterogeneous biomolecules is essential for setting patient-centric specifications. It help...

1 year ago
Reply
RE: CRO or Dossier Holder responsible for Specification

"The dossier holder (client) is responsible for the specifications, even if the product is manufactured by a CRO. The CRO may propose or assist in dev...

1 year ago
Reply
RE: Production specification (NOR) and Regulatory specifications (POR) without DoE

"Planification is or should always be possible even for biological products this means that planning for doing DoEs to define NOR and PAR is available...

1 year ago
Reply
RE: Established conditions CGT

"I think in general, one could always overthink ECs. Nonetheless, in earlier phases with little prior knowledge, effort is needed to set up ECs. It is...

1 year ago
Reply
RE: Analytical Target Profile

"The implementation of the Analytical Target Profile (ATP) within the company involved several important aspects. Initially, the ATP served as a tool ...

1 year ago
Reply
RE: Robustness

"Robustness testing is a frequently debated topic, particularly regarding how and when it should be performed. Guidelines are often interpreted to mea...

1 year ago
Page 6 / 7

Advertisement

Advertisement

Advertisement